|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | ONE JOHNSON & JOHNSON PLAZA |
Address2 |
|
City | NEW BRUNSWICK |
State | NJ |
Zip Code | 08933 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 20686-12
|
||||||||
|
6. House ID# 303480000
|
TYPE OF REPORT | 8. Year | 2020 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Jane Adams |
Date | 1/21/2021 10:37:48 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
- Issues related to spending and linked to corporate tax rate
- H.R.1711/S.780 - No Tax Breaks for Outsourcing Act, regarding all provisions
- H.R.1712/S.779 - Stop Tax Haven Abuse Act, regarding all provisions
- Issues related to CFC look through.
- Issues related to the implementation of the Tax Cut and Jobs Act of 2017
- H.R. 1922/S. 1089 -"Restoring Access to Medication Act of 2019", regarding all provisions.
- H.R. 748/ S. 3458, "Coronavirus Aid, Relief, and. Economic Security Act", regarding tax provisions and future stimulus bills.
- Issues related to supply chain investment incentives.
- Tax issues related to Puerto Rico
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jane |
Adams |
|
|
|
David |
Kavanaugh |
|
|
|
Darrel |
Jodrey |
|
|
|
Riley |
Swinehart |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
- H.R. 863 - DXM Abuse Prevention Act of 2019, regarding all provisions
- S. 726 - Personal Care Products Safety Act, regarding all provisions
- Issues related to the regulation of over-the-counter drugs
- Issues related to cosmetic regulatory reform
- Issues related to cosmetic animal testing
- Issues related to biosimilars
- Issues related to maternal mortality
- Issues related to contact lens safety
- Issues related to medical product communications
- Issues related to medical product review
- Issues related to ingredient safety
- Issues related to diversity in clinical trials
- Issues related to health care pricing transparency
- Issues related to peripheral artery disease
- H.R. 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions
- Issues related to drug importation
- S. 2543, "Prescription Drug Pricing Reduction Act of 2019", regarding all provisions
- H.R. 19, "Lower Costs, More Cures Act of 2019", regarding all provisions
- H.R. 748/ S. 3458, "'Coronavirus Aid, Relief, and. Economic Security Act'', regarding all provisions
- H.R. 6074, "Coronavirus Preparedness and Response Supplemental Appropriations Act", regarding all provisions
- H.R. 6201, "Families First Coronavirus Response Act", regarding all provisions
- H.R. 3975, the Contact Lens Prescription Verification Modernization Act, regarding all provisions
- H.R. 5663, the Safeguarding Therapeutics Act, regarding all provisions
- Issues related to counterfeit health care goods
- S. 3468, Preventing Essential Medical Device Shortages Act of 2020
- Issues related to counterfeit medical devices and combination products and authority to destroy counterfeit medical products
- Issues related to reporting medical device shortages
- Issues related to pandemic response
- S. 2740, "Over the Counter Monograph Safety, Innovation, and Reform Act of 2019", regarding all provisions
- H.R. 5279, "Cosmetic Safety Enhancement Act", regarding all provisions
- H.R. 4296, "Safe Cosmetics and Personal Care Products Act of 2019", regarding all provisions
- Issues related to social determinants of health
- H.R. 5076/S. 1872, "Protecting Seniors Through Immunization", regarding all provisions
- H.R.6062, "To amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes", regarding all provisions.
- H.R.6952, "To direct the President to appoint a Medical Supplies Response Coordinator to coordinate the efforts of the Federal Government regarding the supply and distribution of certain supplies and equipment relating to COVID-19", regarding all provisions
- S.3942, "Securing America's Medical Supply Chain and Advancing the Production of Life Saving Medicines Act", regarding all provisions
- S.3945, "Bring Entrepreneurial Advancements To Consumers Here In North America Act", regarding all provisions
- S.3780, "HOME Act", regarding all provisions
- S.3781, "PART Act", regarding all provisions
- Issues related to diversity in clinical trials
- Issues related to 340B
- S.4613, The Contact Lens Rule Modernization Act, regarding all provisions
- H.R.3107, "Improving Seniors Timely Access to Care Act of 2019, regarding all provisions
- Executive Order 13948: Lowering Drug Prices by Putting America First
- Executive Order 13939: Lowering Prices for Patients by Eliminating Kickbacks to Middlemen
- Executive Order 13938: Increasing Drug Importation To Lower Prices for American Patients
- Executive Order 13937: Access to Affordable Life-Saving Medications
-H.R.133 - Consolidated Appropriations Act, 2021, including legislation regarding average sales price (ASP) reporting requirements for certain hyaluronic acid (HA) products that are classified as devices, but reimbursed as drugs under Medicare Part B
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jane |
Adams |
|
|
|
Darrel |
Jodrey |
|
|
|
David |
Kavanaugh |
|
|
|
Michael |
Barnard |
|
|
|
Kelly |
Waters |
|
|
|
Leif |
Brierley |
|
|
|
Riley |
Swinehart |
|
|
|
Meghan |
Stone |
|
|
|
Abigail |
Pinkele |
|
|
|
Larry |
Camm |
|
|
|
Deana |
McRae |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
-Issues related to FY2020 Appropriations, specifically The Global Fund, Food & Drug Administration, Commerce, Interior, National Institutes of Health and Environmental Protection Agency budgets.
-Issues related to frontline health workers
-Issues related to maternal mortality and morbidity
-H.R. 6800, "Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act", regarding all provisions
-Issues related to contact lenses
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Darrel |
Jodrey |
|
|
|
Jane |
Adams |
|
|
|
Kelly |
Waters |
|
|
|
Leif |
Brierley |
|
|
|
Meghan |
Stone |
|
|
|
Larry |
Camm |
|
|
|
Riley |
Swinehart |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
-Issues related to new tariff proclamations and retaliation.
- Issues related to mandatory supply chain requirements, including under Buy America.
- H.R.6930, "MADE in America Act of 2020", regarding all provisions
- 301 investigation of countries related to foreign digital service taxes and potential tariff retaliation
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Kavanaugh |
|
|
|
Michael |
Barnard |
|
|
|
Leif |
Brierley |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
- Issues related to reimbursement
- HR 1425, "The Patient Protection and Affordable Care Enhancement Act", regarding all provisions
- Issues related to antimicrobial resistance
- Issues relating to vaccine coverage
- Issues related to prior authorization in Medicare for certain medical procedures, including cervical spine fusion
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Barnard |
|
|
|
Riley |
Swinehart |
|
|
|
Abigail |
Pinkele |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
- Issues related to VA medical device procurement issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jane |
Adams |
|
|
|
Riley |
Swinehart |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOR
16. Specific lobbying issues
- Issues related to civil justice reform.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jane |
Adams |
|
|
|
Riley |
Swinehart |
|
|
|
Michael |
Barnard |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
- Patent Trade Office reforms
- H.R.1499 "Protecting Consumer Access to Generic Drugs Act of 2019", regarding all provisions
- S. 1419, "Early Participation in Regulations Act of 2019", regarding all provisions
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Kavanaugh |
|
|
|
Michael |
Barnard |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENV
16. Specific lobbying issues
- H.R. 1834 - Defending our National Marine Sanctuaries from Damaging Chemicals Act of 2019, regarding all provisions
- H.R. 2588/S. 1371 - Oxybenzone and Octinoxate Impact Study Act of 2019, regarding all provisions
- H.R. 2587/S. 1375 - Reef Safe Act of 2019, regarding all provisions
- Issues related to sterilization of medical devices
- Issues regarding environmental sustainability
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Darrel |
Jodrey |
|
|
|
Meghan |
Stone |
|
|
|
Riley |
Swinehart |
|
|
|
Kelly |
Waters |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LBR
16. Specific lobbying issues
- Issues related to corporate governance
- Issues related to diversity & inclusion
- Issues related to racial equity and justice
- Issues related to livability reform protections
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Larry |
Camm |
|
|
|
Kelly |
Waters |
|
|
|
Jane |
Adams |
|
|
|
Riley |
Swinehart |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SCI
16. Specific lobbying issues
- Issues related to data privacy.
- Issues related to artificial intelligence.
- Issues related to cybersecurity.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leif |
Brierley |
|
|
|
Riley |
Swinehart |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |